NYSE · Healthcare
ELI LILLY & Co (LLY)
As-reported financials and recent SEC filings for ELI LILLY & Co, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$65.18B
Net income
$20.64B
Net margin
31.7%
Diluted EPS
$22.95
ROE
77.8%
P/E (TTM)
40.3×
Market cap
$1.01T
Debt / equity
1.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Gross profit | $54.13B | $36.63B | $27.04B | $21.91B | $21.01B |
| Operating income | — | — | — | — | — |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
25-NSE2026-06-02
View on EDGAR →1442026-05-28
View on EDGAR →1442026-05-22
View on EDGAR →8-K2026-05-20
View on EDGAR →1442026-05-20
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →42026-05-19
View on EDGAR →Go deeper on LLY
Search ELI LILLY & Co’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.